Adynxx Company Description

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases.

It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain.

The company was founded in 2007 and is headquartered in San Francisco, California.

Adynxx, Inc.

Country	United States
Founded	2007
Industry	Biotechnology
Sector	Healthcare
Employees	6
CEO	Richard Orr

Contact Details

Address: 100 Pine Street San Francisco, Delaware 94111 United States
Phone	415-512-7740

Stock Details

Ticker Symbol	ADYX
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US00784D1037
SIC Code	2834

Key Executives

Name	Position
Richard Orr Esq., J.D.	President, Chief Executive Officer, Principal Financial Officer and Director
William Martin	Executive Vice President of Corporate Development and Operations
Dina Gonzalez	Principal Accounting Officer and Senior Vice President of Finance
Kimberley Hebert	Senior Director of Clinical Operations